Stay updated with breaking news from 09057220. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Citigroup lowered shares of Bio-Rad Laboratories (NYSE:BIO – Free Report) from a buy rating to a neutral rating in a research note released on Wednesday, MarketBeat reports. Citigroup currently has $365.00 price objective on the medical research company’s stock, down from their prior price objective of $400.00. Other equities research analysts have also recently issued […]
GAM Holding AG bought a new stake in Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 1,001 shares of the medical research company’s stock, valued at approximately $323,000. Several other institutional investors have […]
Federated Hermes Inc. boosted its position in Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report) by 34.6% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 61,728 shares of the medical research company’s stock after purchasing an additional 15,871 shares during the period. Federated Hermes […]
Mutual of America Capital Management LLC cut its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report) by 4.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,921 shares of the medical research company’s stock after selling 148 shares during the […]
Grantham Mayo Van Otterloo & Co. LLC raised its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report) by 6.9% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 82,443 shares of the medical research company’s stock after purchasing an additional 5,339 shares during the […]